News & Media

Recent updates from Arcutis.

April 23, 2021

Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021

April 19, 2021

Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX)

April 12, 2021

Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years

March 26, 2021

Arcutis Announces Updates to its Executive Team

March 18, 2021

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

March 17, 2021

Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference 2021

February 25, 2021

Arcutis to Present at the Cowen 41st Annual Health Care Conference

February 18, 2021

Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff

February 16, 2021

Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

February 16, 2021

Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock

February 2, 2021

Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock

February 1, 2021

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download